Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PRP/OSI sustained-release Macugen collaboration

Executive Summary

A PR Pharmaceuticals/OSI collaboration to develop sustained-release Macugen, announced Jan. 11, grants OSI rights to license PRP's ProPhase encapsulation technology. Under the agreement, PRP will develop the new formulations of the neovascular age-related macular degeneration therapy and test article for non-clinical and clinical trials, while OSI will manage clinical development, manufacturing and marketing. PRP will receive an undisclosed up-front payment from OSI, which recently acquired Macugen (pegaptanib) developer Eyetech, as well as future milestone payments and royalties on net sales of any product resulting from the collaboration. Macugen is expected to face competition in the AMD market from Genentech's Lucentis in early 2006 (1"The Pink Sheet" Nov. 28, 2005, p. 4)...

You may also be interested in...

OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen

An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts